Bangkok--Apr 12--Aziam Burson-Marsteller
The increasingly popular BOTOX procedure for reducing frown lines has received regulatory approval from Canadian Health Authorities. This is the first cosmetic approval based on a clinical test program for BOTOX.
BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex is produced by Allergan Inc. The Canadian approval is specifically for the treatment of prominent frown lines, known as glabellar lines, associated with what the medical profession identifies as excess muscle activity of certain face muscles.
Researchers conducted a double-blind, non drug-controlled study of 264 men and women aged from 23 to 76. A statistically and clinically significantly higher responder rate was demonstrated by the group treated with BOTOX compared with the non drug-treated group.
BOTOX met both primary measurements of effectiveness, which were the investigator's rating of glabellar line severity at maximum frown and the subject's global assessment of change in appearance. At day 30, the timepoint of peak effect, the investigator's rating of a significant reduction in the severity of glabellar lines occurred in 83.7% of the subjects treated with BOTOX versus 1.6% of subjects treated with placebo. Also a significant change in appearance as rated by the subject's self-assessment occurred in 90.1% of the BOTOX-treated group versus 1.6% of the non drug-treated group.
The most frequently reported adverse event was headache, which was reported for 15.3% of subjects treated with BOTOX and 15% of subjects treated with placebo. The only adverse event reported more frequently for subjects treated with BOTOX than for subjects treated with placebo was eyelid or brow drooping (5.4% versus 0%). Other adverse events reported for at least 3% of subjects treated with BOTOX were infection (respiratory), nausea, flu syndrome and muscle weakness. The incidence for these adverse events in the non drug-treated group was comparable.
"The approval in Canada marks a significant step forward in our global strategy to seek additional indications for BOTOX," said Allergan's President of Research and Development and Global BOTOX, Lester J Kaplan, PhD. "Our research and development team has been studying BOTOX for over 10 years and has established a leadership position for multiple new uses of botulinum toxins."
GK Kannan, BOTOX Product Line Head for Asia-Pacific, commented: "This significant approval by the Canadian authorities demonstrates the unsurpassed efficacy and safety of BOTOX in frown lines. It is now the one and only officially approved procedure among similar products. We are looking forward to receiving the similar approvals across Asia and we are working with the authorities across Asia to make this happen soon."
BOTOX global net product sales for the year ended 31 December 2000 were $239.5 million. In January 2001, Allergan submitted a Supplemental Biologics License Application to the U.S. Food and Drug Administration for BOTOX for the treatment of glabellar lines.
For further information:
Burson-Marsteller Hong Kong
Georgette Lee
(852) 2963 5660
Christina Koh
(852) 2963 5672
Marion McDonald
Marketing Manager - Dermatology
Asia Pacific Region
Allergan Asia Limited
Tel: (852) 2401-5821
Fax: (852) 2428-3318
Email: mcdonald_mario[email protected] End.
-AN-